Form 4: Haemonetics Corp: VP, Chief Accounting Officer Reports Acquisition of Restricted Stock Units and Stock Options

Maryanne Farris Maunsell, VP, Chief Accounting Officer of Haemonetics Corp, reports the acquisition of restricted stock units and stock options.

Summary

• On May 17, 2024, Maryanne Farris Maunsell, VP, Chief Accounting Officer of Haemonetics Corp, reported the acquisition of 587 shares of common stock in the form of restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Haemonetics Corp's common stock when vested.
• The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date.
• Maunsell also acquired 1,291 non-qualified stock options with an exercise price of $95.73.
• These options vest in annual increments of 25% beginning on the first anniversary of the grant date and expire on 05/17/2031.
• Following the reported transactions, Maunsell beneficially owns 1,144 shares of common stock, including unvested RSUs previously reported, and 1,291 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option grants to an executive, indicating standard compensation practices.

Positives

• The acquisition of RSUs and stock options suggests confidence in the company's future performance from a key executive.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a multi-year commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's prospects.

Stakeholder Impact

• The acquisition of shares and options by a key executive can be viewed positively by shareholders, as it aligns management's interests with those of the shareholders.

Key Dates